Emyria Ltd
ASX:EMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Emyria Ltd
ASX:EMD
|
AU |
|
F
|
Focused Photonics Hangzhou Inc
SZSE:300203
|
CN |
|
G
|
Grand House Mulia Tbk PT
IDX:HOMI
|
ID |
|
M
|
Magna Gold Corp
XTSX:MGR
|
CA |
|
O
|
Ocean Power Technologies Inc
AMEX:OPTT
|
US |
|
Anglogold Ashanti PLC
F:HT3
|
UK |
|
Darmi Bersaudara Tbk PT
IDX:KAYU
|
ID |
|
Bodhtree Consulting Ltd
BSE:539122
|
IN |
|
S
|
Smurfit Kappa Group PLC
F:SK3
|
IE |
|
S
|
Sumi Indo Kabel Tbk PT
IDX:IKBI
|
ID |
|
Jammu and Kashmir Bank Ltd
NSE:J&KBANK
|
IN |
|
B
|
BioDelivery Sciences International Inc
F:BD5
|
US |
|
K
|
Kailuan Energy Chemical Co Ltd
SSE:600997
|
CN |
|
R
|
Rekatech Capital Bhd
KLSE:REKATECH
|
MY |
|
Super Telecom Co Ltd
SSE:603322
|
CN |
Emyria Ltd
Emyria Ltd. is a healthcare technology and services company. The firm provides care for its patients through its clinics gathering real-world-evidence (RWE) insights in relation to therapies, such as cannabinoid-based medicines and drug development. Its evidence-based drug development program (EMD-003) is focused on mental health and EMD-004 is focused on irritable bowel syndrome (IBS). The Company’s subsidiaries include Emyria Clinical Network Pty Ltd and Openly Care Inc.
Emyria Ltd. is a healthcare technology and services company. The firm provides care for its patients through its clinics gathering real-world-evidence (RWE) insights in relation to therapies, such as cannabinoid-based medicines and drug development. Its evidence-based drug development program (EMD-003) is focused on mental health and EMD-004 is focused on irritable bowel syndrome (IBS). The Company’s subsidiaries include Emyria Clinical Network Pty Ltd and Openly Care Inc.
